Volume 2.22 | Jun 10

Cord Blood News 2.22, June 10, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events


Lupus Study Shows Promising Results Using Umbilical Cord Mesenchymal Stem Cells
A new study shows that umbilical cord mesenchymal stem cell transplant may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus. [Press release from Beike Biotechnology Company Limited discussing online prepublication in Arthritis and Rheumatism]

Need to expand CD34+ cells?
StemSpan® serum-free expansion media are optimized for expanding hematopoietic stem and progenitor cells


Scientists Give the Go-Ahead for Private Storage of Stem Cells from Umbilical Cord Blood
Four world-renowned stem cell experts have recently given their full support to private cord blood banking. The four scientists supported the “Family Cord Blood Bank” which has just been established in the U.S. by CORD:USE. [Press release from the Cryo-Save Group] 

SPRYCEL® (Dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec® in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced Phase III study results in which SPRYCEL (dasatinib) 100 mg once daily demonstrated a superior rate of confirmed complete cytogenetic response compared to Gleevec® (imatinib mesylate). [Press release from Bristol-Myers Squibb Company discussing online prepublication in the New England Journal of Medicine]

New Data Show Novartis Drug Tasigna® Surpasses Glivec® in Slowing Disease Progression for Newly Diagnosed CML Patients
Novartis announced 18-month results (median follow-up) showing that Tasigna® (nilotinib) significantly surpasses Glivec® (imatinib) in slowing disease progression in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. [Press release from Novartis discussing online prepublication in the New England Journal of Medicine]

Study Identifies Promising Treatment for Aggressive Lymphoma
New research illustrates that some patients with transformed lymphoma showed “remarkable” response to lenalidomide, an oral drug with few side effects. [Press release from Mayo Clinic discussing research presented at the American Society of Clinical Oncology Annual Meeting]

UF Oncologists Fight Leukemia with Two-Pronged Therapy, Clinical Trials to Start Within Months
A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow. [University of Florida Press Release]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. [N Engl J Med]

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia. [N Engl J Med]

Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Non-Hodgkin Lymphoma: Results of a Phase II Study
Allogeneic hematopoietic cell transplantation using reduced intensity conditioning offers a potential curative therapy to patients with advanced non-Hodgkin lymphoma. [Blood]

The Human Stem Cell Hierarchy Is Defined by a Functional Dependence on Mcl-1 for Self-Renewal Capacity
Researchers report a role for the Bcl-2 family member myeloid cell leukemia -1 (Mcl-1) as an indispensable regulator of self-renewal in human stem cells, and show that a functional dependence on Mcl-1 defines the human stem cell hierarchy. [Blood]

Interleukin-7 Permits Th1/Tc1 Maturation and Promotes Ex Vivo Expansion of Cord Blood T Cells: A Critical Step toward Adoptive Immunotherapy after Cord Blood Transplantation
Findings offer a major step in fulfilling critical numerical and biological requirements to quickly generate a donor leukocyte infusion product ex vivo using a negligible fraction of a cord blood graft that provides a flexible adoptive immunotherapy platform for both children and adults. [Cancer Res]

Umbilical Cord Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus
Umbilical cord derived mesenchymal stem cell transplantation resulted in amelioration of disease activity, serological changes, and stabilization of proinflammatory cytokines. [Arthritis Rheum]

Tumor Necrosis Factor-Induced Neutrophil Adhesion Occurs Via Sphingosine Kinase-1-Dependent Activation of Endothelial Alpha5Beta1 Integrin
Researchers demonstrate that tumor necrosis factor alpha activates the integrin alpha5beta1 without altering total expression levels of beta1 integrin on human umbilical vein endothelial cells. [Am J Pathol]

Non-Senescent Hsp27-Upregulated MSCs Implantation Promote Neuroplasticity in Stroke Model
In this study, researchers demonstrated that implantation of human umbilical cord mesenchymal stem cells (MSCs) cultured in human umbilical cord serum significantly enhanced neuroplasticity and angiogenesis in stroke and ischemic limb models. [Cell Transplant]

World Marrow Donor Association Framework for the Implementation of HLA Matching Programs in Hematopoietic Stem Cell Donor Registries and Cord Blood Banks
This study defines a comprehensive framework for HLA matching programs, which use intricate algorithms to rapidly select potential donors for a patient from a database and to present these donors in a prioritized list. [Bone Marrow Transplant]

Long-Term Results of High-Dose Chemotherapy with Autologous Bone Marrow or Peripheral Stem Cell Transplant as First Salvage Treatment for Relapsed or Refractory Hodgkin Lymphoma: A Single Institution Experience
Long-term results confirm that high-dose chemotherapy and autologous stem cell or bone marrow transplant was feasible, safe, and very effective. [Leuk Lymphoma]


Tecan Announces OEM Agreement with Global Diagnostics Company
The Tecan Group announced a global OEM agreement with the diagnostics business of Novartis for the supply of a new high-throughput instrument designed to provide blood banks with a flexible, single-platform pooling and archiving solution. [Tecan Trading AG Press Release]

Cleveland Cord Blood Center Participates in Ohio Third Frontier Wright Projects Program Award
The Cleveland Cord Blood Center received notice from the Ohio Third Frontier Wright Projects Program that it has been designated in a 3-year $2.1 million award to collaborate with Case Western Reserve University and Cleveland Clinic Foundation on the project, “Development of a Quantitative Analysis System for Stem Cells.” [PR Newswire]

ISSCR Launches Web Site Providing Information on Stem Cell Treatments
The International Society for Stem Cell Research (ISSCR) announced that it has launched “A Closer Look at Stem Cell Treatments” (www.closerlookatstemcells.org), a web site to arm patients, their families and doctors with information they need to make decisions about stem cell treatments. [International Society for Stem Cell Research Press Release]

BioSante Announces FDA Orphan Drug Designation for GVAX Chronic Myeloid Leukemia Cancer Vaccine
BioSante Pharmaceuticals, Inc. announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia from the FDA’s Office of Orphan Products Development. [BioSante Pharmaceuticals, Inc. Press Release]

ARIAD Presents Updated Clinical Data on Its Investigational Pan-BCR-ABL Inhibitor, AP24534, in Drug-Resistant Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. announced updated clinical data from an ongoing Phase I study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc. Press Release]

Data from Study of Revlimid® in Untreated Patients with Chronic Lymphocytic Leukemia Presented at ASCO
Celgene International Sàrl announced that researchers presented data from an investigator-initiated Phase II study of lenalidomide (Revlimid®) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology (ASCO). [Celgene International Sàrl Press Release]

Soligenix Announces Grant of European Patent for the Treatment of GVHD and Leukemia with Oral Beclomethasone Dipropionate
Soligenix, Inc. announced that the European Patent Office granted patent EP 1830857 “Method of Treatment of Graft-versus-Host Disease and Leukemia with Beclomethasone Diproprionate and Prednisone.” [Soligenix, Inc. Press Release]

Cord Blood Service All Set for Formal Launch
Marking a major step in Qatar’s bid to benefit from stem cell therapies, Virgin Health Bank Qatar Science & Technology Park (VHB QSTP) is to officially launch its cord blood banking services at the Women’s Hospital of Hamad Medical Corporation. [The Gulf Times]


Stroke Prevention Study in Children with Sickle Cell Anemia, Iron Overload Stopped Early
The National Heart, Lung, and Blood Institute has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment. [National Heart, Lung, and Blood Institute Press Release]

FDA Announces Collaboration with Drugs.com
The U.S. Food and Drug Administration announced that it will collaborate with the web site Drugs.com to expand access to the FDA’s consumer health information. [Food and Drug Administration, United States]

Administrative Supplements to Increase Public Awareness of Pediatric Cancers and Available Treatments and Research (NOT-CA-10-026) [National Institutes of Health, United States]

2010 Biological License Application Approvals [Food and Drug Administration, United States]

2010 Biological Device Application Approvals [Food and Drug Administration, United States]

Emerging Infectious Diseases: Evaluation to Implementation for Transfusion and Transplantation Safety Public Workshop (Update) [Food and Drug Administration, United States]


8th International Conference on Cell and Stem Cell Engineering (ICCE2010)
June 11-12, 2010
Dublin, Ireland

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

International Society for Cellular Therapy – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

International Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

AABB (formerly known as the American Association of Blood Banks) Annual Meeting & Cellular Therapy and Transfusion Medicine Expo (CTTXPO) 2010
October 9-12, 2010
Baltimore, United States

Institute for Genomic Medicine Inaugural Symposium
October 11-12, 2010
San Diego, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC)
November 12-13, 2010
Tianjin, China

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Sr. Product Support and Training Specialist (CardianBCT)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cord Blood News.

here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Cord Blood News: Archives  |  Events  |  Subscribe  |  Contact Us